ITONIS HOLDINGS
22951 Mill Creek Drive, Suite A-1
Laguna Hills, California 92653
Phone: 
(949)-200-8887
Email: Office@ItonisHoldings.com
ITONIS HOLDINGS WEBSITE
Its been a long road, our hard work is paying off, and we are confident the Emesyl will be a household name.
Sincerely, Itonis, Inc.
PURCHASE EMESYL HERE⇒ 
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ Itonis, Inc. Announces 10,000 Commercial Spots for Its Emesyl Anti-Nausea Relief Have Begun LAGUNA HILLS, CA--(Marketwired - July 21, 2016) - Itonis, Inc. (OTC PINK: ITNS)
Itonis pleased to announce it received word from its Media Agency that the planned Ten Thousand (10,000) thirty (30) second commercial spots for its Emesyl® Nausea Relief product has begun. The ad is being run in about 240 small cable television systems in over 40 states, and cumulatively makes up a network of approximately 1.0M homes. These runs are at various times day and night, and across all the networks on the platform.
The platform consists of 3 tiers on the following popular cable TV networks:
Image Available: http://www.marketwire.com/…/Tier1-5d69dfd1735ba382be218bded…
The following map shows where the ads are being aired within the states:
Image Available: http://www.marketwire.com/…/map-7d3aea1a7c27ad16a7e1bef3222…
"We've had several shareholder inquiries as to the status of our planned commercials. I can assure you we have been actively engaged with our Media Company pursuing this information on a daily basis. The response to our inquiries and the gathering of this information took a little longer than we expected; however, we're pleased that the ad campaign is finally underway," said Steve Pidliskey, Itonis Vice President.
The Emesyl commercial being run across the network platform can be viewed here: https://wrightmediagroup.com/?portfolio=emesyl-com
If you wish to download a standalone copy of the commercial please click here: http://www.itonisholdings.com/…/1578fee6c35342-emesyl_comme…
If you wish to purchase Emesyl online please click here: http://www.emesyl.com/
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyECheck's patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.
Itonis, Inc. Announces the Results of a Case Study Testing the Effects of Its Emesyl Nasal Relief on Severe Nausea Posted 09:30:00 07/12/2016 by Admin
LAGUNA HILLS, CA--(Marketwired - July 12, 2016) - Itonis, Inc. (OTC PINK: ITNS)
Itonis, Inc. is pleased to announce the results of the case study in which its homeopathic EMESYL® Nausea Relief nasal spray was tested on patients with severe nausea. EMESYL® Nausea Relief contains ginger as one of its active ingredients.
Dr. K. Paul Stoller, M.D. conducted the independent case study in which he tested the acute effects of the EMESYL® Nausea Relief nasal spray on patients who presented with severe nausea. The duration of the patients' nausea symptoms ranged from two to seven hours, and the treatment consisted of one spray of EMESYL® Nausea Relief into each nostril. Upon using EMESYL® Nausea Relief nasal spray, all subjects reported feeling immediately the effects of the product, then leading to relief from nausea -- which ranged from immediate relief to feeling relief in ten minutes.
EMESYL® Nausea Relief is available for purchase online at www.emesyl.com.
"I had hypothesized that the antiemetic effects of ginger may be a result of actions on the central nervous system (CNS), and as such may be more effective if delivered directly to the CNS via a nasal spray," said Dr. Charles Hensley, the inventor and developer of EMESYL®. "Towards this end, EMESYL® Nausea Relief nasal spray was developed and tested," Dr. Hensley added, and he further said, "although large clinical studies need to follow, I am extremely encouraged by Dr. Stoller's results."Dr. Hensley explained, "Due to EMESYL® Nausea Relief's ability to provide quick and lasting relief of nausea through bypassing the gastrointestinal system, it is apparent that the EMESYL® Nausea Relief nasal spray provides convenience to individuals suffering from nausea to treat their nausea symptoms."
Pictures of Emesyl arriving on schedule!
Posted 08:45:00 06/21/2016 by Admin
Our first shipment of Emesyl from National Homeopathic Labs arrived today on schedule.
Stay tuned, we will be scheduling our commercials to air next!
P.S. See more detailed pictures on our Facebook page:
Shareholder update on Manufacturing, Shipping of Product and Commercial Release
Posted 12:55:00 06/15/2016 by Admin
Emesyl manufacturing has been completed. It is bottled, shrink wrapped and set aside in storage waiting to be boxed in our newly designed cartons.
The carton printer has printed and shipped the cartons to the manufacturer yesterday. They are expected to arrive today. Once the manufacture receives them they plan to immediately start boxing the Emesyl, along with stamping the manufacturing date on the box. We expect the finished product to be direct shipped to our office in Laguna Hills by the end of the week.
Once we physically have the finished Emesyl product in our possession we plan to contact the media outlet we used to produce our commercial and authorize the commercials to begin.
Things are on schedule and we will provide further updates as appropriate. Stay tuned!
Emesyl production news update
Posted 08:50:00 06/09/2016 by Admin
This is one of the Emesyl QC bottles taken off the manufacturing line today which will be used for retention. There is a slight change from the original design. It is sealed with a new custom shrink wrap which looks great.
We also re-designed the carton (packaging box) which is now slightly smaller. It also looks great and we should have pictures of the new box sometime next week.
Stay tuned, it's all looking good!
Emesyl Production, Commercials, and Product Ship Update
Posted 03:40:00 05/24/2016 by Admin
To Interested shareholders:
National Homeopathic Labs just confirmed Emesyl production will begin on Monday June 6 and they will ship us finished Emesyl product the week of June 13.
Production was originally scheduled a week earlier, however a slight delay in printing our newly designed unit cartons caused the manufacturing schedule to slide 1 week.
We have also tweaked the content of our commercial prototype and they are ready to air as soon as we provide authorization to begin.
Stay tuned for updates.
Itonis, Inc. announces planned update on 10,000 commercial spots for Emesyl anti-nausea relief
Posted 11:23:00 04/13/2016 by Admin
LAGUNA HILLS, CA – (April 13, 2016) - Itonis, Inc. (OTC PINKSHEETS: ITNS)
Itonis is pleased to announce that it will begin airing its planned Ten Thousand (10,000) thirty (30) second commercial spots for its Emesyl product upon delivery of its first batch of product from National Homeopathic Labs.
A previously signed agreement to provide marketing and public relations services for its Emesyl product calls for placing the 10,000 commercial spots in select regional areas on the most popular cable television networks available. The networks available to Itonis for airing selection choice include ESPN, CNN, Fox News, Discovery Channel, SPIKE, AMC, TBS, Lifetime, A&E, Comedy Central, TV Land, Nickelodeon, Travel Channel, ESPN2, USA, HLN, BET, MTV, SyFy, CMT, TLC, TNT, and FX, etc., and have the ability to air more frequently in any of these select networks.
“The closing of Oasis Health Products forced us to put a hold on this commercial launch until we could secure additional product, and now our new relationship with National Homeopathic Labs allows us to move forward as planned. We’re extremely excited that our Emesyl commercials will finally become a reality,” said Steve Pidliskey, Itonis Vice President.
Itonis, Inc. announces selection of new manufacturer for Emesyl anti-nausea relief
Posted 09:30:00 03/28/2016 by Admin
LAGUNA HILLS, CA (March 28, 2016) - Itonis, Inc. (OTC PINKSHEETS: ITNS)
Itonis, Inc. is pleased to announce that National Homeopathic Labs will be the new manufacturer for its anti-nausea product, Emesyl. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements for over 25 years.
Itonis has placed its first purchase order with National Homeopathic Labs and is expecting delivery of its first batch of product within the next 2 months.
We are very pleased to be working with National Homeopathic Labs and look forward to a long standing relationship with them said Steve Pidliskey, Itonis Vice President. Once they delivered the first batch of samples to us and we had time to test them, we immediately knew we had a sure winner.
Timeline News: CLICK HERE FOR ALL NEWS
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
EMESYL IS FROM THE SAME INVENTOR AS ZICAM DR CHARLES HENSLEY PHD, President of Itonis
Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis Pharmaceuticals Announce First Product
IRVINE, CA--(Marketwire - Aug 20, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) cold remedy, are pleased to announce plans to introduce their first product offering since the creation of Itonis Pharmaceuticals, a division of Itonis. The new division will concentrate on marketing over-the-counter and prescription preparations to treat both common ailments and chronic diseases.
Over the coming weeks, Dr. Hensley and Itonis Pharmaceuticals will outline plans to introduce into the marketplace an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.
Dr. Hensley commented, "I consult for many corporations in the product development and strategic marketing arena but I am especially excited about leading the Itonis Pharmaceuticals team in bringing this product to market. I believe the time is right to begin introduction of what I believe will be a revolutionary product. There have been relatively few innovations within this product category over the past few years and we believe the market is ripe for a new type of nausea preparation that is available over-the-counter. We believe this new preparation will be both safe and effective for a wide range of nausea related conditions."
While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.
Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.
Dr. Hensley has joined the Itonis team to lead the Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs.
EXCERPT FROM DR HENSLEY 6/2/2014 The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues. The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company.
ITONIS PHARMACEUTICALS Itonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam(R) Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.
Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
Dr. Hensley commented, "We had wide success upon creating the Zicam? Cold Remedy and I believe that similar preparations can be created to treat many other common ailments. We plan to launch several products into this derivative pharmaceutical category over the coming months. It is exciting to be a part of this new venture and we plan to move expeditiously into the marketing of the formulations that we plan to announce."
Dr. Hensley has joined Itonis as President of its Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions.
|
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
MANAGEMENT TEAM
Dr.Charles B. Hensley, PH.D
President of Itonis Holdings
Dr. Charles B. Hensley is the pioneer in the development and use of safe and effective therapeutic cocktails. He is a graduate of the University of Oklahoma and received his Ph.D. in Physiology and Biophysics from the University of Southern California.
In the mid 1990's, Dr. Hensley invented of Zicam(R) cold remedy, one of the top cold remedies in the United States. With the launch of ZICAM, Dr. Hensley and co-workers changed the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley also developed Zicam(R) Allergy and the nasal delivery systems used in the Zicam(R) product line extensions.
Dr. Hensley was CEO and Chairman of Nasal Therapeutics, Inc., CEO of PRB Pharmaceuticals, president of Zengen, and co-founder of Zicam, LLC (formerly Geltech, LLC).
Mark Cheung CEO / President
Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.
Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20 staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.
Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.
Steve Pidliskey Vice President / Secretary
Mr. Pidliskey serves as Vice President and Secretary for Itonis, Inc. He is responsible for the management of all company operations and is a visionary leader with a proven track record in motivating, managing and growing large multi-level teams in support of new products and services.
Prior to joining Itonis, Inc. in 2011, Mr. Pidliskey was a Project Executive for IBM Corporation, retiring after a 32 year career. During his tenure with IBM, he was responsible for worldwide sales and services support with contract revenues exceeding $1B annually. He has extensive experience in leading large complex teams responsible for business operations, strategic planning, change management, business process reengineering, and technical sales support. As an Innovative leader, Mr. Pidliskey is known for building strong teams, integrating strategic business partnerships, and delivering high levels of client satisfaction to customer sets ranging from small and medium size businesses to Fortune 500 companies.
Within his community, Mr. Pidliskey has served as a county board member for more than 20 years to a local county government Citizens Advisory Council. He has held several executive positions on the council, and meets monthly with government and community leaders to assist in the development and perpetuation of crime prevention programs in support of law enforcement services. In addition, Mr. Pidliskey has served for over 10 years as a committee member to a local Boy Scout troop and remains active in leading fund raising activities in support of the Boy Scouts of America.
Donald Jolly, Ph.D. CFO / Treasurer
Dr. Donald L. Jolly, Ph.D. has more than 20 years experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a California bank provided him valuable experience in managing the early developments of a business.
Dr. Jolly also serves as the Chairman and CEO of the Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in Hyperbarics. He has studied in London, Aberdeen, Scotland and California with internationally renowned doctors, developed research facilities in California, worked in Africa and Romania, and made great strides in research as well as the application of Hyperbaric Oxygen Therapy (HBOT). This pursuit has supplemented his banking career with additional operational and business growth experience.
Press Release Coordinator 
Security Symbol: ITNS
OTC PINK
Share Structure | | Market Value1 | $5,897,121 | a/o Jun 23, 2016 | | | Authorized Shares | 1,800,000,000 | a/o Feb 29, 2016 | | | Outstanding Shares | 1,205,955,289 | a/o Feb 29, 2016 | | | -Restricted | Not Available | | | -Unrestricted | Not Available | | | Held at DTC | Not Available | | | Float | 1,018,861,540 | a/o Feb 29, 2016 | | | Par Value | 0.001 | | Shareholders of Record | 662 | a/o Feb 29, 2016 |  
| |
|
Itonis Holdings has signed a Licensing Agreement with MyECheck, Inc. for Itonis to acquire a software license for MyECheck's patented mobile payment app that will facilitate point of purchase transactions for medical marijuana, gambling, and general retail sales. 
Itonis Holdings has signed a letter of intent with Valley Organics Inc. for retail use of MyECheck's patented mobile payment application that will facilitate point of purchase transactions for medical marijuana. 